UT Southwestern scientists develop method of synthesizing antibodies

December 28, 1999

DALLAS - December 29, 1999 - UT Southwestern Medical Center at Dallas researchers have discovered a method that may lead to the long-hoped-for efficient and inexpensive production of synthetic antibody substitutes for use in medical diagnostics, biotechnology and biomedical research.

Reporting in January's Nature Biotechnology, the investigators explained how they set up a selection system to find peptides that mimic antibodies by binding to specific peptide epitopes, amino-acid compounds that can combine with antibodies. The scientists were interested in finding relatively small molecules, such as peptides, that could substitute for antibodies, which are crucial proteins in biomedical science but are fragile, and time-consuming and expensive to make.

Antibodies recognize and bind tightly to foreign substances, or antigens, in the body setting up an immune response to fight illnesses. They also can be cloned to use as probes to diagnose illnesses or to study antigens in the laboratory.

"The core of this research is to devise a way to design relatively small molecules that aren't proteins but can recognize a particular run of amino acids, or an epitope," said Dr. Thomas Kodadek, professor of internal medicine and biochemistry and an investigator for UT Southwestern's Center for Biomedical Inventions. "This is important because antibodies are large and must be produced using animals, so they are difficult and expensive to make. They are also fragile, which limits their application outside of carefully controlled laboratory environments.

"But this research gives us the potential to make sensors to detect biowarfare agents, and a number of other things, that are more field-practical in places such as the Saudi Arabian desert, than are antibody-based sensors."

The scientists genetically engineered bacteria so if a cell contained the desired epitope-binding peptide, it would survive an otherwise lethal viral infection. This provided a method to rapidly and easily sort through a large collection of peptides for those few with the desired epitope-binding properties.

Kodadek said that they believe the antibody substitutes or peptides are already useful in some biomedical research for detecting or purifying certain proteins. But the peptides don't bind as tightly as antibodies do to epitopes, so one of the next goals for the investigators is to increase the affinity of the peptides for the epitopes.

Other researchers who contributed to this study were graduate student Zhiwen Zhang and postdoctoral fellow Dr. Weiguang Zhu.

The Welch Foundation and the Texas Advanced Research Program provided funding for this study.
To automatically receive news releases from UT Southwestern via e-mail, send a message to UTSWNEWS-REQUEST@listserv.swmed.edu.
Leave the subject line blank and in the text box, type SUB UTSWNEWS

UT Southwestern Medical Center

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.